As 2021 marks a major milestone for RAS therapeutics, with the first ever KRAS targeted therapy receiving FDA approval, the once undruggable RAS family of proteins is no longer impossible to crack. With this significant industry shift, this community will no doubt continue going from strength to strength and the future looks bright for future development of RAS targeted therapies that safely, effectively, and selectively drug all RAS driven cancers beyond those caused by G12C mutation. There has been no better time to unite the leaders of the field to discuss, connect and network with your biopharma and academic peers at the largest and leading global RAS forum.

With the FDA granting breakthrough designation to Mirati Therapeutic’s Adagrasib in NSCLC patients with the KRAS-G12C mutation, , we were delighted to bring to you exclusive in-depth insight from the leaders of the field as executives from Amgen & Mirati Therapeutics shared their data-driven successes, updates, challenges and future RAS directed strategies

Uniting the largest community of thought leaders and experts in Oncology, Cancer Therapeutics and Clinical Development, September was the definitive and comprehensive roadmap to discuss robust monotherapies or combination strategies capable of specifically targeting different RAS-mutant cancer cells with less toxicity to enhance the impact of RAS therapies against all RAS driven cancers beyond lung. 

As we incorporated tracks taking a deep dive into accelerating emerging modalities, validating robust combination strategies and advancing clinical development, the community joined to gain extensive strategic and scientific information to support development of safe and effective next generation RAS targeted therapies.